Literature DB >> 19642173

Adenosine diphosphate-ribosylation factor 6 is required for epidermal growth factor-induced glioblastoma cell proliferation.

Ming Li1, Jide Wang, Samuel S M Ng, Chu-Yan Chan, Ming-Liang He, Fang Yu, Lihui Lai, Chao Shi, Yangchao Chen, David T Yew, Hsiang-Fu Kung, Marie Chia-Mi Lin.   

Abstract

BACKGROUND: : Epidermal growth factor (EGF) signaling plays a pivotal role in gliomagenesis. The authors previously demonstrated that adenosine diphospate-ribosylation factor 6 (ARF6), a member of the Ras-related small guanosine-5'-triphospate-binding protein family, is required for EFA6A-induced glioma cell migration and invasion. However, the role of ARF6 in EGF signaling is unknown.
METHODS: : The authors analyzed messenger RNA (mRNA) levels of ARF6 and EGF receptor (EGFR) in 16 high-grade glioma samples and in 6 low-grade glioma samples by reverse transcriptase-polymerase chain reaction analysis. To determine whether EGF induces ARF6 expression in human glioblastoma U87 cells through transcriptional regulation and EGFR activation, the levels of ARF6 were assayed in EGF-treated U87 cells that were preincubated with a transcriptional inhibitor (actinomycin D) and an EGFR tyrosine kinase inhibitor (PD153035), respectively. The downstream signaling of EGFR-mediated ARF6 up-regulation also was investigated using specific inhibitors of mitogen-activated protein kinase (MEK), phosphatidylinositol 3' kinase (PI3K), and Janus kinase 2. The involvement of SP1 in the downstream signaling was studied by using an SP1 inhibitor (mithramycin A). Small-interfering RNAs (siRNAs) targeting ARF6 were used to investigate the effects of ARF6 on EGF-mediated glioma cell proliferation.
RESULTS: : The results demonstrated that ARF6 and EGFR mRNA levels were elevated in glioma tissues. Furthermore, EGF stimulated ARF6 expression in U87 cells in a dose-dependent and time-dependant manner. This stimulation was caused by increased transcription of ARF6 and by activation of the MEK/extracellular signal-regulated kinase 1 and 2 (ERK1/2) and PI3K signaling pathways. It is noteworthy that SP1 was essential for EGF-induced ARF6 up-regulation. Finally, EGF-induced glioblastoma cell proliferation depended on ARF6, because the suppression of ARF6 by siRNA or by a dominant-negative mutant significantly inhibited EGF-induced cell proliferation.
CONCLUSIONS: : The results of the current study suggested that EGF-induced ARF6 expression plays a significant role in glioma cell proliferation. Cancer 2009. (c) 2009 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19642173     DOI: 10.1002/cncr.24550

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  19 in total

1.  Association between epidermal growth factor receptor amplification and ADP-ribosylation factor 1 methylation in human glioblastoma.

Authors:  Concha López-Ginés; Lara Navarro; Lisandra Muñoz-Hidalgo; Enrique Buso; José Manuel Morales; Rosario Gil-Benso; Mariela Gregori-Romero; Javier Megías; Pedro Roldán; Remedios Segura-Sabater; José Manuel Almerich-Silla; Daniel Monleón; Miguel Cerdá-Nicolás
Journal:  Cell Oncol (Dordr)       Date:  2017-06-19       Impact factor: 6.730

2.  The small GTPase ARF6 regulates protein trafficking to control cellular function during development and in disease.

Authors:  Allie H Grossmann; Helong Zhao; Noah Jenkins; Weiquan Zhu; Jackson R Richards; Jae Hyuk Yoo; Jacob M Winter; Bianca Rich; Tara M Mleynek; Dean Y Li; Shannon J Odelberg
Journal:  Small GTPases       Date:  2016-12-21

3.  Cationic dirhodium carboxylate-catalyzed synthesis of dihydropyrimidones from propargyl ureas.

Authors:  Miao Yang; Shannon J Odelberg; Zongzhong Tong; Dean Y Li; Ryan E Looper
Journal:  Tetrahedron       Date:  2013-07-08       Impact factor: 2.457

4.  Induction of nonapoptotic cell death by activated Ras requires inverse regulation of Rac1 and Arf6.

Authors:  Haymanti Bhanot; Ashley M Young; Jean H Overmeyer; William A Maltese
Journal:  Mol Cancer Res       Date:  2010-08-16       Impact factor: 5.852

5.  ARF6 Is an Actionable Node that Orchestrates Oncogenic GNAQ Signaling in Uveal Melanoma.

Authors:  Jae Hyuk Yoo; Dallas S Shi; Allie H Grossmann; Lise K Sorensen; ZongZhong Tong; Tara M Mleynek; Aaron Rogers; Weiquan Zhu; Jackson R Richards; Jacob M Winter; Jie Zhu; Christine Dunn; Ashok Bajji; Mark Shenderovich; Alan L Mueller; Scott E Woodman; J William Harbour; Kirk R Thomas; Shannon J Odelberg; Kirill Ostanin; Dean Y Li
Journal:  Cancer Cell       Date:  2016-06-02       Impact factor: 31.743

6.  GEP100/Arf6 is required for epidermal growth factor-induced ERK/Rac1 signaling and cell migration in human hepatoma HepG2 cells.

Authors:  ZhenZhen Hu; Jun Du; Ling Yang; YiChao Zhu; Yu Yang; DaTong Zheng; Akimasa Someya; Luo Gu; Xiang Lu
Journal:  PLoS One       Date:  2012-06-11       Impact factor: 3.240

7.  TD-60 links RalA GTPase function to the CPC in mitosis.

Authors:  Diana Papini; Lars Langemeyer; Maria A Abad; Alastair Kerr; Itaru Samejima; Patrick A Eyers; A Arockia Jeyaprakash; Jonathan M G Higgins; Francis A Barr; William C Earnshaw
Journal:  Nat Commun       Date:  2015-07-09       Impact factor: 14.919

8.  Increased expression of ARF GTPases in prostate cancer tissue.

Authors:  Claire Morgan; Paul D Lewis; Lynda Hopkins; Stephanie Burnell; Howard Kynaston; Shareen H Doak
Journal:  Springerplus       Date:  2015-07-12

9.  Cyclin D1 induction of Dicer governs microRNA processing and expression in breast cancer.

Authors:  Zuoren Yu; Liping Wang; Chenguang Wang; Xiaoming Ju; Min Wang; Ke Chen; Emanuele Loro; Zhiping Li; Yuzhen Zhang; Kongming Wu; Mathew C Casimiro; Michael Gormley; Adam Ertel; Paolo Fortina; Yihan Chen; Aydin Tozeren; Zhongmin Liu; Richard G Pestell
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

10.  Melanoma risk loci as determinants of melanoma recurrence and survival.

Authors:  Justin Rendleman; Shulian Shang; Christine Dominianni; Jerry F Shields; Patrick Scanlon; Christina Adaniel; Alexis Desrichard; Michelle Ma; Richard Shapiro; Russell Berman; Anna Pavlick; David Polsky; Yongzhao Shao; Iman Osman; Tomas Kirchhoff
Journal:  J Transl Med       Date:  2013-11-04       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.